

Cite this: *J. Mater. Chem. B*, 2022,
10, 3916

Inverting glucuronidation of hymecromone *in situ* by catalytic nanocompartments†

Maria Korpidou,^{id}^a Viviana Maffei,^{ab} Ionel Adrian Dinu,^{id}^{ab}
Cora-Ann Schoenenberger,^{id}^{ab} Wolfgang P. Meier^{id}^{ab} and Cornelia G. Palivan^{id}^{*ab}

Glucuronidation is a metabolic pathway that inactivates many drugs including hymecromone. Adverse effects of glucuronide metabolites include a reduction of half-life circulation times and rapid elimination from the body. Herein, we developed synthetic catalytic nanocompartments able to cleave the glucuronide moiety from the metabolized form of hymecromone in order to convert it to the active drug. By shielding enzymes from their surroundings, catalytic nanocompartments favor prolonged activity and lower immunogenicity as key aspects to improve the therapeutic solution. The catalytic nanocompartments (CNCs) consist of self-assembled poly(dimethylsiloxane)-*block*-poly(2-methyl-2-oxazoline) diblock copolymer polymersomes encapsulating β -glucuronidase. Insertion of melittin in the synthetic membrane of these polymersomes provided pores for the diffusion of the hydrophilic hymecromone–glucuronide conjugate to the compartment inside where the encapsulated β -glucuronidase catalyzed its conversion to hymecromone. Our system successfully produced hymecromone from its glucuronide conjugate in both phosphate buffered solution and cell culture medium. CNCs were non-cytotoxic when incubated with HepG2 cells. After being taken up by cells, CNCs produced the drug *in situ* over 24 hours. Such catalytic platforms, which locally revert a drug metabolite into its active form, open new avenues in the design of therapeutics that aim at prolonging the residence time of a drug.

Received 1st February 2022,
Accepted 22nd April 2022

DOI: 10.1039/d2tb00243d

rsc.li/materials-b

1. Introduction

Living organisms use metabolism for the biotransformation of endogenous and exogenous substances, such as drugs. During the metabolic processes, hydrophilic derivatives are created which lead to rapid excretion and elimination from the body.¹ In most cases, drugs with shorter half-life tend to act quickly with their effects wearing off rapidly. As a result, more frequent administrations or higher doses are needed which can lead to abuse of these compounds and even addiction.^{2,3} Hence, the alteration of the pharmacodynamic and pharmacokinetic parameters of rapidly metabolized drugs is the focus of intense research. One state-of-the-art approach involves the entrapment or encapsulation of the active molecules in lipid or polymer-based nanocarriers that offer a more controlled and/or targeted drug delivery.^{4–6} These delivery systems were shown to enhance the biodistribution, pharmacokinetics,

stability and solubility of the active compounds.⁷ However, low drug loading capacity, toxicity associated with high concentrations and environmental concerns are major limitations of these nanocarriers when it comes to mass production and market release.⁸

An important step in overcoming these limitations is the development of nanocompartments confining enzymes able to convert prodrugs into drugs in order to achieve a spatially and/or temporally controlled drug production.^{9–12} These biosynthetic nanocompartments protect the encapsulated enzymes from their surroundings, leading to prolonged activity and less immunogenicity.^{13–15} When appropriately selected, polymer-based compartments offer several advantages over liposomes,^{16,17} such as enhanced mechanical and colloidal stability,¹⁸ tuneable permeability¹⁹ and stimuli responsiveness.^{20,21} Enzyme biopharmaceuticals have been encapsulated in different types of nanocompartments in order to improve their properties, including stability against degradation or reduced toxicity.²² For example, *L*-asparaginase (ASNase), used to treat leukaemias and lymphomas has been encapsulated in polyion complex vesicles (PICsomes)²³ and in permeable, asymmetric polymersomes.²⁴ When systemically injected into mice, ASNase PICsomes exhibited sustained conversion of *L*-asparagine in the blood stream due to their prolonged blood circulation compared with free ASNase.²³ While in this study

^a Department of Chemistry, University of Basel, Mattenstrasse 24a, BPR 1096, 4058, Basel, Switzerland. E-mail: cornelia.palivan@unibas.ch

^b NCCR-Molecular Systems Engineering, Mattenstrasse 24a, BPR 1095, 4058, Basel, Switzerland

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d2tb00243d>



the enzyme itself was acting as the therapeutic, and the shielding effect from the encapsulation was pivotal, encapsulation of β -galactosidase in carbohydrate-*b*-poly(propylene glycol) derived vesicles (CAPsomes), which are intrinsically permeable to small molecular weight molecules, afforded the conversion of a co-administered prodrug into an active compound in addition to protecting the enzyme from degradation.¹¹ Advances in nanocompartments designed for enzyme replacement therapy,^{23,25,26} cancer treatment^{11,12} and other applications^{10,27,28} *in vitro* and/or *in vivo* have increased the interest and research in the field. Inverting metabolic inactivation of a drug *in situ* is a novel concept that has yet to be explored.

Hymecromone or 4-methylumbelliferone (4-MU) is an inhibitor of hyaluronan synthesis and primarily used as a drug in bile therapy.²⁹ More recently, its effectiveness in treating other diseases such as cancer,³⁰ type 1 diabetes³¹ and COVID-19³² is being explored. Hymecromone is rapidly metabolized to 4-methylumbelliferol glucuronide (4-MUG) in the liver.³³ Owing to its poor pharmacokinetics and quick elimination from the body (oral bioavailability < 3%, $t_{1/2}^{\beta} = 28$ min) due to glucuronidation, the daily administered hymecromone dose may rise up to 2400 mg.^{30,34,35}

In this study, we created catalytic nanocompartments based on polymersomes rendered permeable by melittin biopores that confine β -glucuronidase (GUS) in their cavity. These catalytic nanocompartments (CNCs) are designed to catalyse the conversion of a pro-drug or metabolite from its glucuronide form to the active compound *in vitro* and in cells (Fig. 1). We chose bacterial GUS for encapsulation as it cleaves the glucuronide moiety from a variety of molecules under a broad range of conditions (pH 5.5–7.8 and temperatures up to 60 °C),^{36–38} and explored the production of active 4-MU from the glucuronide conjugate 4-MUG which is the main 4-MU metabolite found in the body.³⁹

Polymersomes self-assembled from poly(dimethylsiloxane)-*block*-poly(2-methyl-2-oxazoline) amphiphilic block copolymers are recognized for their stealth properties, non-toxicity, and biocompatibility.^{16,40} Hence, we generated polymersomes by self-assembly of PDMS₂₅-*b*-PMOXA₁₀, a diblock copolymer where the short hydrophobic PDMS block facilitates melittin insertion resulting in the permeabilization of the polymersome membrane.^{41–43} A porous membrane was pivotal to our CNC design in order to provide a pathway for hydrophilic substrates and products to and from the nanocompartment cavity containing GUS.^{41,43,44} In the present study, we report the physicochemical characterization of GUS CNCs and their enzymatic efficiency in phosphate buffered solution (PBS) and cell culture medium. To explore the potential of CNCs for therapeutic applications, we examined cellular toxicity, uptake into cells and intracellular activity of GUS CNCs. In this regard, we used HepG2 cells, since they are derived from liver where hymecromone is mainly glucuronidated.³³ Our catalytic nanocompartments are unique in that they represent a prototype for the locally confined transformation of a prodrug/metabolite to an active compound which makes them a stepping stone toward a whole new field of biomedical applications.




Fig. 1 Schematic representation of the catalytic nanocompartment containing GUS and its enzymatic activity. Melittin pores in the PDMS₂₅-*b*-PMOXA₁₀ membrane provide a pathway to from the compartment interior where β -glucuronidase (GUS) catalyses the production of hymecromone (4-MU) from its glucuronide conjugate (4-MUG) within cells that have taken up CNCs.

2. Experimental

2.1 Materials

B-glucuronidase (GUS, *E. coli* Type VII-A), melittin (from honey bee venom), 4-methylumbelliferol- β -D-glucuronide (4-MUG), proteinase K (from *Tritirachium album*), fluorescent dye Atto647, penicillin, streptomycin, L-glutamine, Sepharose[®] (4B, 45–165 μ m beads diameter), and Whatman[®] Nucleopore[™] Track-Etched membranes (100 nm) were purchased from Sigma-Aldrich (USA). Atto488 *N*-hydroxysuccinimide ester (Atto488 NHS-Ester) was purchased from ATTO-TEC (Germany). Enhanced Pierce bicinchonic acid (BCA) assay, and wheat germ agglutinin – Alexa Fluor[™] 555 conjugate were purchased from Thermo Fisher Scientific (USA). Phosphate buffered saline (PBS) and fetal bovine serum (FBS) were purchased from BioConcept (Switzerland). Minimum essential medium and non-essential amino acids (NEAA) were purchased from Gibco Life Sciences (USA). CellTiter 96[®] Aqueous One Solution Cell Proliferation Assay (MTS) and Hoechst 33342 trihydrochloride trihydrate were purchased from Invitrogen (USA).

2.2 Nanocompartment preparation

Synthesis and characterization of amphiphilic diblock copolymer poly(dimethylsiloxane)₂₅-*block*-poly(2-methyl-2-oxazoline)₁₀ (PDMS₂₅-*b*-PMOXA₁₀) were described previously.⁴¹ A membrane thickness of 12 ± 0.8 nm for self-assembled PDMS₂₅-*b*-PMOXA₁₀ polymersomes was determined from cryogenic transmission electron micrographs.⁴²

Polymersomes containing enzymes, henceforth termed catalytic nanocompartments (CNCs) and 'empty' polymersomes were prepared using the film rehydration method. In brief, a thin



film of PDMS₂₅-*b*-PMOXA₁₀ (5 mg mL⁻¹ polymer in EtOH) was formed by rotary evaporation of the solvent (100 rpm at 40 °C, 160 mbar for 45 min). For the preparation of permeabilized CNCs containing GUS (GUS-melCNCs), the polymer film was rehydrated in the dark in PBS (pH 7.2) containing β-glucuronidase (0.4 mg mL⁻¹, 25 kU) and melittin (50 μM), by stirring overnight at room temperature (RT). Polymersomes without melittin pores and enzyme (PSS), melittin-permeabilized polymersomes (melPSS), and CNCs without melittin (GUS-CNCs) were obtained by rehydrating the polymer film with PBS, PBS and melittin, and PBS and β-glucuronidase, respectively. For Atto647-labeled polymersomes (Atto647-PSS), the film was rehydrated with PBS containing Atto647 (0.02 mg mL⁻¹). Following self-assembly, nanocompartments were incubated with proteinase K (0.05 mg mL⁻¹) for 2 hours at 37 °C to remove non-encapsulated protein, followed by extrusion (10 times) through a 100 nm Whatman Nuclepore polycarbonate membrane. Size exclusion chromatography (SEC) on a Sepharose[®] 4B (45–165 μm beads diameter) column equilibrated in PBS was performed for further purification. Nanocompartment suspensions were stored at 4 °C until further use.

2.3 Characterization of nanocompartments

2.3.1 Light scattering. Dynamic light scattering (DLS) experiments were performed using a Zetasizer Nano ZSP (Malvern Instruments Ltd., U.K.) at RT. A laser wavelength of 633 nm and a scattering angle of 173° were used. Samples were diluted to a final concentration of 0.3 mg mL⁻¹ polymer. Measurements were carried out in triplicate and each measurement consisted of 11 runs.

Static light scattering (SLS) experiments were performed on a light scattering spectrometer (LS instruments, Switzerland), equipped with a He-Ne 21 mW laser (λ = 632.8 nm) at scattering angles from 30° to 135° at 25 °C. The samples were diluted to 0.03 mg mL⁻¹ final concentration of polymer in order to reduce multiple scattering. The radius of gyration (*R_g*) was obtained from the SLS data using Guinier plots, while the hydrodynamic radius (*R_h*) was obtained from DLS.⁴⁵

2.3.2 Nanoparticle tracking analysis (NTA). Nanoparticle tracking analysis (NTA) was performed using a NanoSight NS 300 instrument (NanoSight Ltd, U.K.) equipped with a 532 nm laser. The samples were diluted to 0.0125 mg mL⁻¹ of polymer and applied to the viewing chamber. Three videos of 60 s were captured at RT for each measurement. The NTA software (version 3.4, NanoSight) was used to analyze the movement of nanocompartments based on tracking each particle on a frame-by-frame basis (Brownian motion) in order to obtain their mean and median size, together with the estimated concentration of nanocompartments in solution.

2.3.3 Transmission electron microscopy (TEM). CNCs (5 μL, 0.2 mg mL⁻¹) were adsorbed on 400 mesh copper grids for 1 min, washed with water, and blotted to remove excess liquid. Specimens were negatively stained with uranyl acetate (2%) for 10 sec, washed and blotted. Transmission electron microscopy micrographs were recorded on a Philips CM100 with an accelerating voltage of 80 kV.

2.3.4 Fluorescence correlation spectroscopy. For labelling GUS with fluorescent dye, the enzyme was incubated in the dark with a 7-fold excess of Atto488 NHS-Ester in dimethylformamide (DMF) for 48 hours at 4 °C under stirring conditions. Unconjugated dye was removed by SEC (Sepharose[®] 4B, 45–165 μm beads diameter) using PBS for equilibration and elution.

For fluorescence correlation spectroscopy (FCS), an inverted laser scanning confocal microscope (LSM 880, Carl Zeiss, Germany) with a water immersion objective (Zeiss C/Apochromat, *M* = 40, NA = 1.2) was used. An Argon laser (wavelength 488 nm) with appropriate filter (MBS 488) was used to excite Atto488. The pinhole size (34 μm, 1 AU) was adjusted before recording FCS curves of the free dye.

For FCS measurements, 20 μL of the free fluorophore, fluorophore labelled-enzyme or polymersomes in PBS (1:2 dilution), were placed on a 0.15 mm thick glass coverslip mounted on the microscope stage. Fluorescence signals from free fluorophore, Atto488-labeled enzyme and polymersomes loaded with Atto488-labeled enzyme were measured in a real time (5 s with 30 repetitions) and autocorrelation function was obtained by a QuickFit 3.0 software calculator. The experimental autocorrelation curves for the free fluorophore were fitted according to eqn (1) with a one component diffusion model:

$$G(\tau) = 1 + \left(1 + \frac{T}{1-T} e^{-\left(\frac{\tau}{\tau_{\text{trip}}}\right)}\right) \frac{1}{N} \left[\frac{1}{1 + \frac{\tau}{\tau_D} \sqrt{1 + R^2 \frac{\tau}{\tau_D}}} \right] \quad (1)$$

where *N* represents the average number of particles in the observation volume, τ_D is the diffusional correlation time and *R* is the structural parameter, set to 5. *T* is the fraction of molecules in triple state, while τ_{trip} is the triplet time. The diffusion coefficient *D* was calculated using the relation between the *x*-*y* dimension of the confocal volume (*ω_{xy}*) and τ_D as in following eqn (2):

$$\tau_D = \frac{\omega_{xy}^2}{4D} \quad (2)$$

Two component diffusion model, presented in eqn (3) was used for fitting the experimental autocorrelation curves for the free labelled enzyme and the nanocompartment encapsulating labelled enzyme:

$$G(\tau) = 1 + \left(1 + \frac{T}{1-T} e^{-\left(\frac{\tau}{\tau_{\text{trip}}}\right)}\right) \frac{1}{N} \left[\frac{f_1}{1 + \frac{\tau}{\tau_{D1}} \sqrt{1 + R^2 \frac{\tau}{\tau_{D1}}}} \right] + \frac{1}{N} \left[\frac{f_2}{1 + \frac{\tau}{\tau_{D2}} \sqrt{1 + R^2 \frac{\tau}{\tau_{D2}}}} \right] \quad (3)$$

The number of dye molecules per enzyme (NPE) was calculated by eqn (4):

$$\text{NPE} = \frac{\text{Counts per molecule}_{\text{enzyme}}}{\text{Counts per molecule}_{\text{free dye}}} \quad (4)$$



The number of enzymes per nanoreactor (NPN) was calculated by eqn (5):

$$\text{NPN} = \frac{\text{Counts per molecule}_{\text{nanocompartment}}}{\text{Counts per molecule}_{\text{free dye}}} \quad (5)$$

2.3.5 BCA assay for determining enzyme encapsulation efficiency. In the case of unlabeled β -glucuronidase, the amount of enzyme inside nanocompartments was calculated by subtracting the amount of protein released after rupturing CNCs from the initial amount of protein added to the film rehydration solution. Protein was quantified using the enhanced Pierce bicinchonic acid (BCA) assay according to the supplier's protocol with the following modifications; a calibration curve was prepared with different concentrations of GUS rather than with bovine serum albumin. Non-permeabilized GUS-CNCs were first ruptured by sonication and then incubated with ethanol at a ratio of 3:1 (v/v) for 1 hour at 37 °C. The solution was filtered through 0.2 μm nylon membrane, 4 mm filter (Whatman™, General Electric, U.K.) and added at a 1:2 ratio to the BCA reagent. Samples and GUS standards were incubated for 2 hours at 37 °C, and the absorbance was measured at 562 nm using a SpectraMax id3 plate reader (Molecular Devices, USA).

2.4 Enzyme activity assays

Fluorescence assays were performed using 96-well, flat bottom black plates (Thermo Fisher Scientific). The increase of fluorescence was measured at λ_{ex} (365 nm) and λ_{em} (445 nm) in a SpectraMax id3 microplate reader (Molecular Devices, USA). 4-Methylumbelliferyl- β -D-glucuronide (4-MUG, 5 μM) was added to CNCs (1.25 mg mL⁻¹, [GUS] 24 U mL⁻¹) or the respective amount of free enzyme in solution (24 U mL⁻¹) in a final volume of 200 μL PBS or minimum essential medium containing 10% FBS ('MEM') per well. 4-MUG (5 μM) without CNCs or free enzyme was added in PBS or MEM as control. All assay conditions were performed in triplicate. Fluorescence emission was monitored for 90 min at 37 °C.

For estimating drug production, the fluorescence intensity of 0, 5, 10, 20, 40 μM 4-MU either in PBS or MEM was measured and a calibration curve was prepared. Hymecromone production from 4-MUG by free and encapsulated GUS was calculated based on the calibration curve at time points when the reaction reached maximum fluorescence intensity ($t = 10$ min for free GUS in PBS, $t = 90$ min for GUS-melCNCs in PBS, $t = 30$ min for free GUS in MEM, $t = 60$ min for GUS-melCNCs in MEM).

For the evaluation of enzyme stability, free GUS, GUS-melCNCs and GUS-CNCs were stored in PBS for 2 months at 4 °C. After filtration through a 100 nm Whatman Nuclepore polycarbonate membrane, 5 μM 4-MUG were added and the increase in fluorescence was monitored for 90 min at 37 °C. The activity of aged samples was compared to that of freshly prepared samples at 18 min (time point of 4-MU maximum catalysed by free GUS) and at 60 min (time point of 4-MU maximum catalysed by GUS-CNCs).

Kinetic parameters for free enzyme and GUS-melCNCs were calculated using the Michaelis-Menten model:

$$v = \frac{V_{\text{max}}[S]_0}{K_{\text{M}} + [S]_0}$$

$$k_{\text{cat}} = \frac{V_{\text{max}}}{[E]_0}$$

where v is the velocity of the enzyme, V_{max} is the maximum velocity at saturating concentration, $[S]_0$ is initial the concentration of the substrate S, K_{M} is the Michaelis-Menten constant, k_{cat} is the turnover number, and $[E]_0$ is the concentration of catalytic sites, equivalent with the concentration of enzyme.

GUS-melCNCs or free GUS in solution ([GUS] 24 U mL⁻¹) were incubated with increasing concentrations of 4-MUG in PBS (30, 90, 150, 300, 600, 750 μM) or MEM (80, 120, 200, 400, 800 μM). The increase in fluorescence associated with the production of hymecromone was monitored over 1 hour at 37 °C, and K_{M} , V_{max} , and k_{cat} values were calculated.

2.5 Cell culture

HepG2 cells (hepatocellular carcinoma, human; ATCC® HB-8065™) were routinely cultured in minimum essential medium supplemented with 10% FBS, 100 U mL⁻¹ penicillin, 100 U mL⁻¹ streptomycin, 1% L-glutamine and 1% non-essential amino acids. Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO₂.

2.5.1 Cell viability assay. Cell viability was evaluated by CellTiter 96® Aqueous One solution cell proliferation assay (MTS) following the supplier's protocol. In brief, cells were seeded at a concentration of 2000 cells per well in a 96 well plate (100 μL). After 24 hours, the medium was removed and replaced with 150 μL of fresh MEM mixed with 50 μL of nanocompartments in PBS (1.25 mg mL⁻¹), free enzyme ([GUS] 24 U mL⁻¹) or PBS. The cells were then cultured at 37 °C for another 24 h. The MTS reagent (20 μL) was added to each well and after 2 hours at 37 °C absorbance was measured at 490 nm using a SpectraMax plate reader. The data was normalized to PBS treated control cells after background absorbance removal.

2.5.2 Cellular uptake and imaging. Cells were seeded at a concentration of 25 000 cells (in 200 μL MEM) in each well of an ibidi 8-well chambered glass bottom coverslip (Vitaris, Switzerland). After 24 hours, the medium was replaced with fresh MEM containing either Atto647-labeled polymersomes (Atto647-PSs, 1.25 mg mL⁻¹) or the respective amount of PBS as a control. After 24 h incubation, cells were gently washed with PBS (3 \times). Nuclei were stained by incubating cells with a 20 000-fold dilution of Hoechst 33342 fluorescent dye (20 mins, 37 °C), followed by 3 washing steps with PBS. Cells were fixed with 4% paraformaldehyde (15 mins at RT), followed by rinsing with PBS (3 \times). Fixed cells were incubated with wheat germ agglutinin-Alexa Fluor™ 555 conjugate (200-fold dilution, 10 min at RT) for membrane staining. The cells were washed with PBS (3 \times) and imaged by confocal laser scanning microscopy (LSM 880, Carl Zeiss, Germany) using an oil immersion objective (Zeiss, 63 \times Plan-Apochromat, NA 1.4). Images were recorded using a 633 nm HeNe laser to visualize Atto647-PSs



(detection range: 643–758 nm), a 561 nm DPSS 5561-10 laser for Alexa Fluor™ 555 (detection range: 570–615 nm), and a UV laser for Hoechst 33342 detection (detection range: 415–470 nm). The images were analyzed using the ZEN 3.2 software (blue edition) and Imaris software (Bitplane) for 3D reconstructions.

2.5.3 Activity of CNCs in HepG2 Cells. HepG2 cells were seeded in a black 96-well, flat bottom plate at a concentration of 2000 cells per well (100 μ L) and incubated at 37 °C and 5% CO₂. The next day, the medium was replaced with 150 μ L fresh MEM mixed with 50 μ L nanocompartment solution (1.25 mg mL⁻¹), free enzyme or PBS (untreated control). All conditions were carried out in triplicate. After 24 hours incubation at 37 °C and 5% CO₂, the supernatant was removed, cells were washed with PBS, and 180 μ L fresh MEM was added. 4-MUG was added in a final concentration of 400 μ M (20 μ L) and the fluorescence was recorded at several timepoints over 24 hours. Control cells were incubated with 20 μ L of PBS as substrate. To estimate hycromone production, reference values were obtained by directly incubating corresponding cultures with 400 μ M 4-MU.

3. Results and discussion

3.1 Formation and characterization of CNCs

We selected the diblock copolymer PDMS₂₅-*b*-PMOXA₁₀ to generate catalytic nanocompartments (CNCs) because its short block lengths result in the self-assembly of polymersomes whose thin membrane is conducive to the insertion of pore-forming membrane proteins.^{27,46} In addition, polymersomes assembled from block copolymers based on PDMS and PMOXA are predisposed for biomedical applications as many times they have been shown to be non-toxic and biocompatible.^{16,41} However, in the body, these block copolymers are non-degradable and excreted mainly *via feces*.⁴⁷ The nanocompartments were formed by the film rehydration method where organic solvents that can adversely affect enzymes and peptides are avoided.^{41,48} To obtain membrane-permeabilized CNCs encapsulating bacterial β -glucuronidase (GUS-melCNCs), a thin PDMS₂₅-*b*-PMOXA₁₀ film was rehydrated with a mixture

of enzyme and pore-forming melittin in phosphate buffered saline (PBS). In addition, polymersomes containing GUS but lacking melittin pores (GUS-CNCs) (Fig. S1, S3 and S4, ESI†) and polymersomes permeabilized with melittin but lacking enzymes (melPSs) were prepared as controls. All nanocompartments prepared in this study were incubated with proteinase K prior to their SEC purification in order to remove non-encapsulated enzyme and melittin where applicable.¹⁰

The morphology of our polymersomes was characterized by a combination of light scattering, TEM and NTA.⁴¹ DLS measurements indicated an average diameter of 136 \pm 37 nm for GUS-melCNCs and 137 \pm 37 nm for GUS-CNCs (Fig. 2A, Fig. S1A, ESI†). The hydrodynamic radius (R_h) revealed by the DLS profile and the radius of gyration (R_g) obtained by SLS (Fig. S2 and S3, ESI†) are presented in Table 1. The R_g/R_h ratio or shape parameter, ρ , was around 1 (Table 1), which is typical for the morphology of hollow spheres.^{41,49} The vesicular nature of the polymersomes was further corroborated by TEM (Fig. 2B, Fig. S1B, ESI†). Polymersome concentration was assessed by NTA measurements which also confirmed the narrow size distribution of CNCs (Fig. S4, ESI†). Comparison of GUS-melCNCs with non-permeabilized GUS-CNCs by light scattering techniques, NTA and TEM indicated that melittin-induced membrane permeability had no effect on morphology or dispersity of the nanocompartments. Similarly, we and others have shown that morphology of polymersomes harbouring other enzymes was barely affected by enzyme encapsulation.^{27,41,50}

The autocorrelation curves of standalone Atto488-GUS and CNCs encapsulating Atto488-labeled enzyme were compared to free dye (Fig. 2C and Fig. S1C, ESI†). A shift of the diffusion time (τ_D) calculated from the FCS autocorrelation curve of Atto488-GUS to increased values indicated the successful labelling of the enzyme (τ_D of free dye compared to τ_D of Atto488-GUS, Table S1, ESI†), τ_D of Atto488-GUS being directly correlated to its size.

A further increase of the diffusion time was observed for Atto488-GUS-melCNCs, indicating encapsulated enzyme (τ_D of Atto488-GUS-CNCs compared to τ_D of Atto488-GUS, Table S1, ESI†). By using Stokes-Einstein equation, we calculated the




Fig. 2 Characterization of GUS-melCNCs. (A) Size distribution of GUS-melCNCs measured by DLS (black: intensity, yellow: volume, blue: number; curves represent mean \pm s.d. of 3 replications). (B) TEM micrograph of GUS-melCNCs showing the deflated structure typical for hollow spheres and the variation in their size. (Scale bar: 500 nm) (C) Normalized FCS autocorrelation curves (solid lines) for free Atto488 dye (black), Atto488-GUS (blue) and Atto488-GUS-melCNCs (cyan). Symbols represent raw data and solid lines represent fitted curves.



Table 1 Characterization of GUS–melCNCs and GUS–CNCs

	Radius of gyration (R_g) (nm)	Hydrodynamic radius (R_h) (nm)	ρ (R_g/R_h)	Concentration (polymersomes mL ⁻¹)
GUS–melCNC	69 ± 6	68 ± 7	1.01 ± 0.3	$(3.5 \pm 0.3) \times 10^{12}$
GUS–CNC	62 ± 6	66 ± 2	0.95 ± 0.1	$(3.3 \pm 0.1) \times 10^{12}$

respective sizes of the nanocompartments derived from the FCS diffusion times. Their values were in agreement with the sizes obtained by LS and NTA, indicating that there was no tendency of the CNCs to aggregate (Table S1, ESI[†]). As the overall catalytic activity of CNCs largely depends on the amount of enzyme encapsulated,^{10,27,41,44} we evaluated the encapsulation of GUS by FCS. Based on the molecular brightness of the free fluorophore, Atto488-GUS and Atto488-GUS–melCNCs, we calculated that the enzyme was labelled on average with 1 dye molecule (see eqn (4) above), and 2 molecules of GUS (see eqn (5) above) were encapsulated per CNC. To estimate the number of melittin pores per GUS–melCNC, corresponding polymersomes were prepared that lack GUS but are melittin-permeabilized (melPSS). The total GUS–melCNC concentration (Fig. S4, ESI[†]) and the total amount of melittin present in the melPSS solution was calculated and correlated with the average number of melittin monomers constituting each pore (12),⁵¹ resulting in approximately 200 pores per GUS–melCNC. According to our previous study on melittin pores in PMOXA-*b*-PDMS-*b*-PMOXA membranes, we expect a pore diameter of at least 1 nm.⁴⁶ Our data regarding size and distribution of GUS containing CNCs, enzyme encapsulation (Fig. S5, ESI[†])^{41,52,53} and melittin pore formation^{43,46} are in good agreement with other studies addressing nanocompartments self-assembled by film rehydration of PDMS-*b*-PMOXA block copolymers.

3.2 Catalytic conversion of 4-MUG to hymecromone

The enzymatic activity of free and encapsulated enzyme in solution was evaluated by monitoring the conversion of 4-MUG (5 μM) to hymecromone (4-MU) at 445 nm under different conditions (Fig. 3).⁵⁴ Comparison of GUS activity of free *versus* encapsulated enzyme in PBS is shown in Fig. 3A. Upon addition of 4-MUG to free enzyme (Fig. 3A, blue squares), fluorescence

associated with the catalytic conversion to hymecromone rapidly increased and reached a plateau after about 10 min. In contrast, hymecromone production by GUS–melCNCs (Fig. 3A, cyan circles) constantly increased up to 80 min, and then appeared to plateau. A corresponding behavior was reported for other CNCs⁴⁴ and is attributable to the diffusion time of substrate and product through the (melittin) pores of CNCs. Consistent with this notion, when GUS–CNCs without pores were incubated with 4-MUG, fluorescence at 445 nm remained minimal over time (Fig. 3A, yellow rhombi). This highlights the importance of melittin pores as in their absence, the polymer membrane does not allow for the passive diffusion of 4-MUG towards the confined enzymes. Furthermore, the absence of fluorescence confirms that the incubation of GUS–CNCs with proteinase K prior to their purification successfully eliminated unencapsulated enzymes attached to the outer surface of the membrane. Similarly, 4-MUG by itself showed no increase in fluorescence in PBS (Fig. 3A, black triangles) or cell culture medium with 10% fetal bovine serum (FBS; Fig. 3B, white triangles) which suggests that in the absence of the enzyme, the hydrolysis of the ether bond and therefore production of 4-MU, does not occur. This is in accordance with clinical data showing that only a small percentage of hymecromone glucuronidation is reversible by the β-glucuronidase present in the bacteria of the small intestine.⁵⁵ The stability of the CNCs and their enzymatic activity were assessed with samples stored in PBS at 4 °C for 2 months (Fig. S6, ESI[†]). All our GUS–melCNCs retained their size and virtually full enzymatic activity.

In order to more closely mimic the environmental conditions of living systems,⁵⁶ the activity of free and encapsulated GUS was assessed in culture medium containing 10% FBS (Fig. 3B). Upon addition of 4-MUG to free GUS (Fig. 3B, white squares), fluorescence slowly increased over the first 30 min




Fig. 3 Enzymatic efficiency of CNCs at 37 °C. (A) 4-MUG (5 μM) conversion to 4-MU in PBS, (B) in cell culture medium supplemented with 10% fetal bovine serum (FBS), and (C) in PBS (filled symbols) and cell culture medium (empty symbols), each supplemented with 10% FBS. Squares represent free GUS (24 U mL⁻¹), circles: GUS–melCNCs, rhombi: GUS–CNCs, triangles: corresponding reaction mix without enzyme. Measurements represent triplicates, symbols might overlap.



and then reached a plateau, suggesting molecular crowding related to the presence of 10% FBS decreased the efficiency of hymecromone production. In the case of GUS–melCNCs (Fig. 3B, white circles), the time course of hymecromone production was similar to that in PBS (Fig. 3A, cyan circles), suggesting that the confined enzyme was barely affected by protein-rich serum. The amount of hymecromone produced was estimated based on a 4-MU reference curve (Fig. S7, ESI†). In PBS, approximately 4.5 μM hymecromone were produced by the free enzyme and 3 μM by GUS–melCNCs. In complete cell culture medium, free enzyme was able to produce approximately 4.3 μM of hymecromone, while GUS–melCNCs produced 2.2 μM . The lower levels of hymecromone production by confined GUS are likely to be caused by the restriction of diffusion by the compartment membrane. Furthermore, we investigated the possibility that the drug was entrapped within the polymer membrane (Fig. S8, ESI†). Based on a calibration curve using different concentrations of hymecromone, we calculated that only 4% of the drug produced remains associated with the nanocompartment.

To explore whether the FBS in the cell culture medium accounted for the difference in hymecromone production between free and encapsulated GUS (Fig. 3B), we compared its production in PBS containing 10% FBS (Fig. 3C, filled symbols) to culture medium with 10% FBS (Fig. 3C, empty symbols). Indeed, the difference in hymecromone production between free and encapsulated enzyme was similar for PBS and culture medium. In fact, the FBS interfered with the kinetics of hymecromone production for the free enzyme but not for GUS–melCNCs. Because the GUS inside CNCs is protected by the membrane and only small molecules can diffuse through the pores, molecular crowding brought about by FBS mainly affected the activity of the free enzyme. Notably, in the highly complex environment of living cells, we expect other small molecules to affect the intracellular production of hymecromone by GUS–melCNCs.

3.3 Kinetic analysis of catalytic nanocompartments

The kinetic analysis of both free and encapsulated GUS (GUS–melCNCs) was assessed first in PBS, and then in complete cell culture medium (Table 2).⁵⁶ The kinetic analysis of the reaction was modelled in a first approximation with the Michaelis–Menten kinetics since the substrate (4-MUG) was added in excess (from 100 to 4000-fold molar excess of [4-MUG] over [GUS]) (Fig. S9, ESI†).⁵⁷ CNCs without melittin pores (GUS–CNCs) were not amenable to kinetic analysis since they did not exhibit any drug producing activity (Fig. 3, yellow rhombi).

The encapsulation of enzymes in polymersomes influences their kinetic parameters in several ways: the velocity of the reaction is decreased and the affinity for the substrate is increased.^{44,58} Accordingly, in PBS, K_M and V_{max} of GUS–melCNCs decreased 3 and 1.5 times, respectively, compared to free enzyme (Table 2). Lower K_M values of GUS–melCNCs reflect a higher affinity for the substrate^{44,50,59} which is attributable to the increased probability of an interaction between enzyme and substrate within the confined reaction space. The turnover parameter, k_{cat} , is decreased 1.5-fold for GUS–melCNCs. As k_{cat} indicates the maximum number of 4-MUG molecules that are converted to hymecromone per enzyme per second, any reduction in GUS–melCNCs *versus* free GUS is associated with limited diffusion of 4-MUG and 4-MU by the polymer membrane.⁴⁴

Comparison of the kinetic parameters of free GUS in PBS and MEM revealed a decrease in V_{max} , K_M and k_{cat} in MEM, which could be expected considering the complexity of cell culture medium.^{60,61} It is conceivable that proteins, vitamins and nutrients present in cell culture media might interact with the substrate and/or enzyme, thereby decreasing the efficiency of catalysis. In contrast, the kinetic parameters of the encapsulated GUS in PBS and MEM are comparable. These results taken together suggest that the catalytic efficiency of our GUS–melCNCs is predominantly governed by the influx and efflux of the substrate and product molecules. Based on the enzymatic activity of GUS–melCNCs in cell culture medium we next assessed their activity and efficiency of producing hymecromone in living cells.

3.4 Hymecromone production in cells

In the body, glucuronidation of hymecromone occurs mainly in the liver. Therefore, we chose the liver-derived HepG2 cancer cell line for studying the effects of GUS CNCs *in vitro*.⁶² Our choice was further endorsed by recent findings showing an association of hymecromone with anticancer properties.^{63,64} Confocal laser scanning microscopy of HepG2 cells incubated with Atto647-encapsulating polymersomes (Atto647-PSs) at 1.25 mg mL⁻¹ for 24 hours revealed the presence of Atto647-PSs throughout the cytoplasm (Fig. 4A1–2, Fig. S10A–C, ESI†). Control cells that had not been treated with Atto647-PSs did not show any fluorescence (Fig. 4B, Fig. S10D–F, ESI†).

We addressed the cytotoxicity of CNCs and free enzyme by carrying out MTS proliferation assays with HepG2 cells (Fig. 4C).⁶⁵ None of the nanocompartments nor the free enzyme had a negative impact on the cell viability. Furthermore, although melittin is a bee venom, when inserted as pores in

Table 2 Comparison of kinetic parameters for free and encapsulated GUS

	Free GUS (PBS)	GUS–melCNCs (PBS)	Free GUS (MEM)	GUS–melCNCs (MEM)
K_M (μM)	$(1.2 \pm 0.4) \times 10^3$	$(3.8 \pm 1.4) \times 10^2$	$(1.9 \pm 0.2) \times 10^2$	$(3.4 \pm 1) \times 10^2$
V_{max} ($\mu\text{moles s}^{-1}$)	$(7 \pm 1.7) \times 10$	$(4.2 \pm 1) \times 10$	$(4.2 \pm 0.4) \times 10$	$(3.3 \pm 0.2) \times 10$
k_{cat} (1 s^{-1})	$(2.7 \pm 0.6) \times 10^2$	$(1.6 \pm 0.4) \times 10^2$	$(1.6 \pm 0.2) \times 10^2$	$(1.3 \pm 0.1) \times 10^2$

K_M , Michaelis–Menten constant, V_{max} , maximal enzyme velocity, k_{cat} , turnover rate






Fig. 4 Uptake of Atto647-PSs by HepG2 cells. 3D reconstructions of multiple confocal sections of HepG2 cells incubated with Atto647-PSs (1.25 mg mL^{-1}) for 24 hours (A12, red spheres). (B) HepG2 cells incubated with the respective amount of PBS. Nuclei (blue) were stained with Hoechst 33342 fluorescent dye, cellular membranes (green) with Atto555-WGA fluorescent dye. Scale bar, $5 \mu\text{m}$. (C) Cell viability as percentage of HepG2 cells incubated with only PBS (control, black), GUS-melCNCs (cyan), free GUS (blue), PSs (grey) and melPSs (yellow). Graph shows mean \pm s.d. of three independent experiments.

the CNC membrane at the concentrations indicated, it apparently had no adverse effect on cell proliferation.

To explore the ability of CNCs to produce hymecromone in living cells, we incubated HepG2 cells with either GUS-melCNCs, GUS-CNCs, free GUS or the respective amount of PBS for 24 hours. Subsequently, fresh culture medium containing $400 \mu\text{M}$ 4-MUG was added as, at this concentration, hymecromone was shown to inhibit hyaluronan synthesis in cancer cell lines,^{66–69} and cultures were returned to the 37°C

incubator. The change in fluorescence was recorded at 0, 2, 4, 8, 12 and 24 hours (Fig. 5). After 24 hours, cells that had taken up GUS-melCNCs, showed a fluorescence signal that corresponds to approximately $12 \mu\text{M}$ of hymecromone (see Fig. S7B and S11, ESI[†]). In fact, this amount might be an underestimation as some of the hymecromone produced *in situ* will be metabolized to 4-MUG in cells. Furthermore, although there is a possibility of intracellular components blocking individual melittin pores, considering their transient formation and their number per




Fig. 5 Intracellular production of hymecromone. HepG2 cells were incubated for 24h with CNCs for uptake, washed to remove extracellular CNCs, then exposed to a single dose of $400 \mu\text{M}$ 4-MUG, after which the increase in fluorescence was recorded at 0, 2, 4, 8, 12 and 24 h. GUS-melCNCs (cyan circles), free GUS (blue squares), GUS-CNCs (yellow rhombi), PBS (black triangles). Graph shows mean \pm s.d. of three independent experiments.



CNC, a potential blockage would only be a minor drawback. No increase in fluorescence was observed when untreated cells were incubated with 4-MUG (Fig. 5, black triangles), an indication that HepG2 cells by themselves are not able to produce such levels of hymecromone. However, we cannot exclude that small amounts of 4-MUG are converted to 4-MU by endogenous GUS (Fig. 5, Fig. S11, black triangles, ESI†).³³ In addition, 4-MUG was not converted to 4-MU in cells that were treated with non-permeabilized GUS-CNCs (Fig. 5, yellow rhombi) or with polymersomes lacking GUS (PSS, melPSS, Fig. S12, ESI†).

Free β -glucuronidase applied in clinical treatment was shown to be quickly degraded and to elicit an immune response in patients with Sly syndrome.^{70,71} One of the advantages of polymersomes is that they provide a protective shell for the encapsulated enzyme and thereby prolong its activity.^{13,14} Consistent with this notion, the increase in fluorescence was significantly higher in cells incubated with GUS-melCNCs compared to those incubated with free GUS (Fig. 5, blue squares), confirming that our nanocompartments shield GUS from proteolysis and degradation inside cells.

Our PDMS-*b*-PMOXA based CNCs are prone to accumulation in the liver^{47,72} where they encounter high levels of metabolized hymecromone.⁷³ Undoubtedly, differences in pharmacokinetics will have to be taken into account in order to optimize GUS-melCNC efficiency *in vivo*. Beforehand, however, further studies are necessary to elucidate the bio-distribution of our PDMS-*b*-PMOXA based nanocompartments.

4. Conclusions

Here, we demonstrate the formation of catalytic nanocompartments containing β -glucuronidase that are able to produce hymecromone in HepG2 cells over 24 hours by inverting glucuronidation naturally occurring in the drug's metabolism. The locally confined catalysis of 4-MUG to 4-MU conversion inside cells led to 17-fold higher levels of the drug compared to 4-MUG converted by endogenous glucuronidase. To the best of our knowledge, this is the first report of an intracellular conversion of a metabolite into an active drug. We believe that our nanosystem opens new approaches for extending the lifetime of drugs by counteracting metabolism.

Author contributions

M. K., V. M., I. A. D. and W. P. M. conceived the project. M. K. conducted the experiments. M. K. V. M. and C.A.S analysed the data. W. P. M. and C. G. P. supervised the project. The manuscript was written through contributions of all authors. All authors approved the final version of the manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This project is part of BIOMOLMACS and has received funding from the European Union's Horizon2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement N° 859416. Additional financial support has been obtained from National Centre of Competence in Research – Molecular Systems Engineering (NCCR-MSE) and the University of Basel. The authors further thank Dr V. Mihali for TEM images, Dr M. Skowicki for the support in cell imaging, and Dr M. Kyropoulou for fruitful discussions. The authors also thank Y. Qutbuddin (Max Planck Institute of Biochemistry, Prof. Dr P. Schwille, Munich, Germany) for the support in the drug entrapment study. M.K. personally thanks EU ITN BIOMOLMACS for research funding and support.

References

- 1 L. A. Stanley, in *Pharmacognosy: Fundamentals, Applications and Strategy*, ed. S. Badal and R. Delgoda, Academic Press, London, 1st edn, 2017, pp. 527–545.
- 2 L. P. Longo and B. Johnson, *Am. Fam. Physician*, 2000, **61**, 2121–2128.
- 3 B. Sproule, B. Brands, S. Li and L. Catz-Biro, *Can. Fam. Physician*, 2009, **55**, 68–69.
- 4 S. Cao, Z. Lv, S. Guo, G. Jiang and H. Liu, *J. Drug Delivery Sci. Technol.*, 2021, **61**, 102124.
- 5 C. Tan, J. Wang and B. Sun, *Biotechnol. Adv.*, 2021, **48**, 107727.
- 6 W. Gu, J. An, H. Meng, N. Yu, Y. Zhong, F. Meng, Y. Xu, J. J. L. M. Cornelissen, Z. Zhong, W. X. Gu, H. Meng, N. Yu, Y. N. Zhong, F. H. Meng, Z. Y. Zhong, J. J. L. M. Cornelissen, J. N. An and Y. Xu, *Adv. Mater.*, 2019, **31**, 1904742.
- 7 K. K. Upadhyay, A. K. Mishra, K. Chuttani, A. Kaul, C. Schatz, J. F. Le Meins, A. Misra and S. Lecommandoux, *Nanomedicine*, 2012, **8**, 71–80.
- 8 V. Dhapte and V. Pokharkar, in *Green Synthesis, Characterization and Applications of Nanoparticles*, ed. A. Shukla and S. Irvani, Elsevier, London, 1st edn, 2019, pp. 321–345.
- 9 J. F. Mukerabigwi, Z. Ge and K. Kataoka, *Chem. – Eur. J.*, 2018, **24**, 15706–15724.
- 10 K. Langowska, C. G. Palivan and W. Meier, *Chem. Commun.*, 2013, **49**, 128–130.
- 11 T. Nishimura, Y. Sasaki and K. Akiyoshi, *Adv. Mater.*, 2017, **29**, 1702406.
- 12 W. Ke, J. Li, F. Mohammed, Y. Wang, K. Tou, X. Liu, P. Wen, H. Kinoh, Y. Anraku, H. Chen, K. Kataoka and Z. Ge, *ACS Nano*, 2019, **13**, 2357–2369.
- 13 R. A. J. F. Oerlemans, S. B. P. E. Timmermans and J. C. M. van Hest, *ChemBioChem*, 2021, **22**, 2051–2078.
- 14 A. Belluati, I. Craciun, C. E. Meyer, S. Rigo and C. G. Palivan, *Curr. Opin. Biotechnol.*, 2019, **60**, 53–62.
- 15 X. Li, X. Zhao, R. Lv, L. Hao, F. Huo and X. Yao, *Macromol. Biosci.*, 2021, **21**, 2000424.
- 16 C. G. Palivan, R. Goers, A. Najer, X. Zhang, A. Car and W. Meier, *Chem. Soc. Rev.*, 2016, **45**, 377–411.



- 17 E. Rideau, R. Dimova, P. Schwille, F. R. Wurm and K. Landfester, *Chem. Soc. Rev.*, 2018, **47**, 8572–8610.
- 18 K. Kumar Upadhyay, J. F. Le Meins, A. Misra, P. Voisin, V. Bouchaud, E. Ibarboure, C. Schatz and S. Lecommandoux, *Biomacromolecules*, 2009, **10**, 2802–2808.
- 19 H. Bermudez, A. K. Brannan, D. A. Hammer, F. S. Bates and D. E. Discher, *Macromolecules*, 2002, **35**, 8203–8208.
- 20 J. Du and R. K. O'Reilly, *Soft Matter*, 2009, **5**, 3544–3561.
- 21 H. Oliveira, E. Pérez-Andrés, J. Thevenot, O. Sandre, E. Berra and S. Lecommandoux, *J. Controlled Release*, 2013, **169**, 165–170.
- 22 F. Bialas, D. Reichinger and C. F. W. Becker, *Enzyme Microb. Technol.*, 2021, **150**, 109864.
- 23 D. Sueyoshi, Y. Anraku, T. Komatsu, Y. Urano and K. Kataoka, *Biomacromolecules*, 2017, **18**, 1189–1196.
- 24 C. Z. Bueno, A. C. Apolinário, A. Duro-Castano, A. Poma, A. Pessoa, C. O. Rangel-Yagui and G. Battaglia, *ACS Macro Lett.*, 2020, **9**, 1471–1477.
- 25 Y. Anraku, A. Kishimura, M. Kamiya, S. Tanaka, T. Nomoto, K. Toh, Y. Matsumoto, S. Fukushima, D. Sueyoshi, M. R. Kano, Y. Urano, N. Nishiyama and K. Kataoka, *Angew. Chem., Int. Ed.*, 2016, **55**, 560–565.
- 26 M. Spulber, P. Baumann, S. S. Saxer, U. Piele, W. Meier and N. Bruns, *Biomacromolecules*, 2014, **15**, 1469–1475.
- 27 C. E. Meyer, J. Liu, I. Craciun, D. Wu, H. Wang, M. Xie, M. Fussenegger and C. G. Palivan, *Small*, 2020, **16**, 1906492.
- 28 B. S. Kim, M. Naito, H. Chaya, M. Hori, K. Hayashi, H. S. Min, Y. Yi, H. J. Kim, T. Nagata, Y. Anraku, A. Kishimura, K. Kataoka and K. Miyata, *Biomacromolecules*, 2020, **21**, 4365–4376.
- 29 S. Takeda and M. Aburada, *J. Pharmacobiodyn.*, 1981, **4**, 724–734.
- 30 N. Nagy, I. Gurevich, H. F. Kuipers, S. M. Ruppert, P. L. Marshall, B. J. Xie, W. Sun, A. V. Malkovskiy, J. Rajadas, M. Grandoch, J. W. Fischer, A. R. Frymoyer, G. Kaber and P. L. Bollyky, *J. Biol. Chem.*, 2019, **294**, 7864–7877.
- 31 N. Nagy, G. Kaber, P. Y. Johnson, J. A. Gebe, A. Preisinger, B. A. Falk, V. G. Sunkari, M. D. Gooden, R. B. Vernon, M. Bogdani, H. F. Kuipers, A. J. Day, D. J. Campbell, T. N. Wight and P. L. Bollyky, *J. Clin. Invest.*, 2015, **125**, 3928–3940.
- 32 W. Li, S. Yang, P. Xu, D. Zhang, Y. Tong, L. Chen, B. Jia, A. Li, C. Lian, D. Ru, B. Zhang, M. Liu, C. Chen, W. Fu, S. Yuan, C. Gu, L. Wang, W. Li, Y. Liang, Z. Yang, X. Ren, S. Wang, X. Zhang, Y. Song, Y. Xie, H. Lu, J. Xu, H. Wang and W. Yu, *EBioMedicine*, 2022, **76**, 103861.
- 33 D. Turgeon, J. S. Carrier, E. Lévesque, D. W. Hum and A. Bélanger, *Endocrinology*, 2001, **142**, 778–787.
- 34 H. F. Kuipers, N. Nagy, S. M. Ruppert, V. G. Sunkari, P. L. Marshall, J. A. Gebe, H. D. Ishak, S. G. Keswani, J. Bollyky, A. R. Frymoyer, T. N. Wight, L. Steinman and P. L. Bollyky, *Clin. Exp. Immunol.*, 2016, **185**, 372–381.
- 35 E. R. Garrett, J. Venitz, K. Eberst and J. J. Cerda, *Biopharm. Drug Dispos.*, 1993, **14**, 13–39.
- 36 X. Song, Z. Jiang, L. Li and H. Wu, *Front. Chem. Sci. Eng.*, 2014, **8**, 353–361.
- 37 S.-J. Yeom, G. H. Han, M. Kim, K. K. Kwon, Y. Fu, H. Kim, H. Lee, D.-H. Lee, H. Jung and S.-G. Lee, *PLoS One*, 2017, **12**, e0170398.
- 38 P. M. Kemp and K. D. Cliburn, Federal Aviation Administration Comparison of Species-Specific β -Glucuronidase Hydrolysis of Cannabinoid Metabolites in Human Urine, Oklahoma City, 2015.
- 39 E. R. Garrett and J. Venitz, *J. Pharm. Sci.*, 1994, **83**, 115–116.
- 40 K. Kiene, S. H. Schenk, F. Porta, A. Ernst, D. Witzigmann, P. Grossen and J. Huwyler, *Eur. J. Pharm. Biopharm.*, 2017, **119**, 322–332.
- 41 C. E. Meyer, I. Craciun, C.-A. Schoenenberger, R. Wehr and C. G. Palivan, *Nanoscale*, 2021, **13**, 66–70.
- 42 R. Wehr, E. C. dos Santos, M. S. Muthwill, V. Chimisso, J. Gaitzsch and W. Meier, *Polym. Chem.*, 2021, **37**, 5377–5389.
- 43 V. Maffeis, A. Belluati, I. Craciun, D. Wu, S. Novak, C. A. Schoenenberger and C. G. Palivan, *Chem. Sci.*, 2021, **12**, 12274–12285.
- 44 A. Belluati, I. Craciun, J. Liu and C. G. Palivan, *Biomacromolecules*, 2018, **19**, 4023–4033.
- 45 A. Guinier and C. B. Walker, in *Small-angle scattering of X-rays*, ed. Mayer M. G., John Wiley & Sons, Inc., New York, 1st edn, 1955.
- 46 A. Belluati, V. Mikhalevich, S. Y. Avsar, D. Daubian, I. Craciun, M. Chami, W. P. Meier and C. G. Palivan, *Biomacromolecules*, 2019, **21**, 701–715.
- 47 K. Liu, X. Wang, X. Li-Blatter, M. Wolf and P. Hunziker, *ACS Appl. Bio Mater.*, 2020, **3**, 6919–6931.
- 48 P. Baumann, M. Spulber, O. Fischer, A. Car and W. Meier, *Small*, 2017, **13**, 1603943.
- 49 D. Daubian, J. Gaitzsch and W. Meier, *Polym. Chem.*, 2020, **11**, 1237–1248.
- 50 Q. Chen, H. Schönherr and G. J. Vancso, *Small*, 2009, **5**, 1436–1445.
- 51 J. H. Lin and A. Baumgaertner, *Biophys. J.*, 2000, **78**, 1714–1724.
- 52 A. Moquin, J. Ji, K. Neibert, F. M. Winnik and D. Maysinger, *ACS Omega*, 2018, **3**, 13882–13893.
- 53 M. Mertz and K. Castiglione, *Int. J. Mol. Sci.*, 2021, **22**, 7134.
- 54 T. Martin, R.-V. Wöhner, S. Hummel, L. Willmitzer and W. B. Frommer, in *Gus Protocols: Using the GUS Gene as a Reporter of Gene Expression*, ed. S. R. Gallagher, Academic press, San Diego, 1st edn, 1992, pp. 23–43.
- 55 P. Dashnyam, R. Mudududdla, T. J. Hsieh, T. C. Lin, H. Y. Lin, P. Y. Chen, C. Y. Hsu and C. H. Lin, *Sci. Rep.*, 2018, **8**, 1–12.
- 56 A. Zotter, F. Bäuerle, D. Dey, V. Kiss and G. Schreiber, *J. Biol. Chem.*, 2017, **292**, 15838–15848.
- 57 L. A. Segel and M. Slemrod, *SIAM Rev.*, 1989, **31**, 446–477.
- 58 S. Varlas, J. C. Foster, P. G. Georgiou, R. Keogh, J. T. Husband, D. S. Williams and R. K. O'Reilly, *Nanoscale*, 2019, **11**, 12643–12654.
- 59 Q. Chen, G. R. Kristin, H. Schönherr and G. J. Vancso, *ChemPhysChem*, 2010, **11**, 3534–3540.
- 60 K. van Eunen and B. M. Bakker, *Perspect. Sci.*, 2014, **1**, 126–130.
- 61 R. Eisenthal, M. J. Danson and D. W. Hough, *Trends Biotechnol.*, 2007, **25**, 247–249.



- 62 R. M. Hoffmann, G. Schwarz, C. Pohl, D. J. Ziegenhagen and W. Kruis, *Dtsch. Med. Wochenschr.*, 2005, **130**, 1938–1943.
- 63 B. Kundu, P. Saha, K. Datta and S. C. Kundu, *Biomaterials*, 2013, **34**, 9462–9474.
- 64 F. Piccioni, M. Malvicini, M. G. Garcia, A. Rodriguez, C. Atorrasagasti, N. Kippes, I. T. Piedra Buena, M. M. Rizzo, J. Bayo, J. Aquino, M. Viola, A. Passi, L. Alaniz and G. Mazzolini, *Glycobiology*, 2012, **22**, 400–410.
- 65 T. M. Buttke, J. A. McCubrey and T. C. Owen, *J. Immunol. Methods*, 1993, **157**, 233–240.
- 66 T. Nakamura, M. Funahashi, K. Takagaki, H. Munakata, K. Tanaka, Y. Saito and M. Endo, *Biochem. Mol. Biol. Int.*, 1997, **43**, 263–268.
- 67 V. B. Lokeshwar, L. E. Lopez, D. Munoz, A. Chi, S. P. Shirodkar, S. D. Lokeshwar, D. O. Escudero, N. Dhir and N. Altman, *Cancer Res.*, 2010, **70**, 2613–2623.
- 68 I. Kakizaki, K. Kojima, K. Takagaki, M. Endo, R. Kannagi, M. Ito, Y. Maruo, H. Sato, T. Yasuda, S. Mita, K. Kimata and N. Itano, *J. Biol. Chem.*, 2004, **279**, 33281–33289.
- 69 I. Kakizaki, K. Takagaki, Y. Endo, D. Kudo, H. Ikeya, T. Miyoshi, B. A. Baggenstoss, V. L. Tlapak-Simmons, K. Kumari, A. Nakane, P. H. Weigel and M. Endo, *Eur. J. Biochem.*, 2002, **269**, 5066–5075.
- 70 P. S. Kishnani, *AAPS Adv. Pharm. Sci. Ser.*, 2015, **19**, 9–21.
- 71 B. H. Biela, L. A. Khawli, P. Hu and A. L. Epstein, *Cancer Biother. Radiopharm.*, 2003, **18**, 339–353.
- 72 C. De Vocht, A. Ranquin, R. Willaert, J. A. Van Ginderachter, T. Vanhaecke, V. Rogiers, W. Versées, P. Van Gelder and J. Steyaert, *J. Controlled Release*, 2009, **137**, 246–254.
- 73 N. Nagy, H. F. Kuipers, A. R. Frymoyer, H. D. Ishak, J. B. Bollyky, T. N. Wight and P. L. Bollyky, *Front. Immunol.*, 2015, **6**, 123.

